PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2075724
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2075724
Crispr Technology Market is estimated to be valued at USD 4,372.8 Mn in 2026 and is expected to reach USD 15,306.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 19.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4,372.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 19.60% | 2033 Value Projection: | USD 15,306.6 Mn |
CRISPR technology is driving advances in genome editing across medicine, pharmaceutical, biotechnology, and agriculture, which has enabled scientists to conduct research in these fields through faster and more efficient genome editing across the world. CRISPR is also used to correct genetic defects, treat human diseases, and yield better crop varieties. It has a number of potential applications that include treating and preventing the spread of diseases, correcting genetic defects, and also, improving crops. The CRISPR-Cas9 system has a wide diversity of applications. In medicine, it has been applied in research related to cancer, virus infections, genetic diseases and detection of pathogens. CRISPR is a technology that can be used to edit genes and, as such, will likely change the world.
The outbreak of COVID-19 across the globe, increasing number of ongoing clinical trials, and expanding research in gene editing tools are some major factors expected to augment growth of the global CRISPR Technology market during the forecast period. For instance, in March 2020, scientists at the University of Toronto developed CHyMErA, a CRISPR-based tool for more versatile genome editing.
CRISPR technology have great potential for application in both the prevention and control of COVID-19. In March 2020, researchers at New York genome center developed a new CRISPR screening technology to target RNA, including RNA of novel viruses (COVID-19). Moreover, in November 2020, researchers at ETH Zurich, Switzerland, swapped CAS9 enzyme for CAS 12a, which allowed the researchers to edit genes in 25 target sites.